# | Title | Journal | Year | Citations |
---|
1 | MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines | Lancet Neurology, The | 2016 | 679 |
2 | Defining high, medium and low impact prognostic factors for developing multiple sclerosis | Brain | 2015 | 403 |
3 | Deep gray matter volume loss drives disability worsening in multiple sclerosis | Annals of Neurology | 2018 | 295 |
4 | Progression of regional grey matter atrophy in multiple sclerosis | Brain | 2018 | 269 |
5 | Myelin-oligodendrocyte glycoprotein antibody-associated disease | Lancet Neurology, The | 2021 | 261 |
6 | Treatment of multiple sclerosis — success from bench to bedside | Nature Reviews Neurology | 2019 | 239 |
7 | The current role of MRI in differentiating multiple sclerosis from its imaging mimics | Nature Reviews Neurology | 2018 | 157 |
8 | MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice | Nature Reviews Neurology | 2020 | 150 |
9 | The hippocampus in multiple sclerosis | Lancet Neurology, The | 2018 | 90 |
10 | Brain Atrophy in Multiple Sclerosis | Neuroimaging Clinics of North America | 2017 | 64 |
11 | Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis | Multiple Sclerosis Journal | 2020 | 54 |
12 | Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study | Neurological Sciences | 2020 | 48 |
13 | Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis | JAMA Neurology | 2023 | 42 |
14 | Optical coherence tomography in multiple sclerosis: A 3‐year prospective multicenter study | Annals of Clinical and Translational Neurology | 2021 | 36 |
15 | EAN guideline on palliative care of people with severe, progressive multiple sclerosis | European Journal of Neurology | 2020 | 23 |
16 | MR Imaging in Monitoring and Predicting Treatment Response in Multiple Sclerosis | Neuroimaging Clinics of North America | 2017 | 20 |
17 | An uncommon first manifestation of multiple sclerosis: Tako-Tsubo cardiomyopathy | Multiple Sclerosis Journal | 2016 | 18 |
18 | Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis | American Journal of Neuroradiology | 2018 | 17 |
19 | Scoring the 10‐year risk of ambulatory disability in multiple sclerosis: the RoAD score | European Journal of Neurology | 2021 | 16 |
20 | Developing a Digital Solution for Remote Assessment in Multiple Sclerosis: From Concept to Software as a Medical Device | Brain Sciences | 2021 | 16 |
21 | Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis | Multiple Sclerosis Journal | 2022 | 16 |
22 | Cerebrospinal fluid kappa free light chains for the diagnosis of multiple sclerosis: A systematic review and meta-analysis | Multiple Sclerosis Journal | 2023 | 15 |
23 | Foveal changes in aquaporin‐4 antibody seropositive neuromyelitis optica spectrum disorder are independent of optic neuritis and not overtly progressive | European Journal of Neurology | 2021 | 14 |
24 | EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis | Journal of Palliative Medicine | 2020 | 13 |
25 | Cumulative Dose of Macrocyclic Gadolinium-Based Contrast Agent Improves Detection of Enhancing Lesions in Patients with Multiple Sclerosis | American Journal of Neuroradiology | 2017 | 12 |
26 | Purified IgG from aquaporin-4 neuromyelitis optica spectrum disorder patients alters blood-brain barrier permeability | PLoS ONE | 2020 | 11 |
27 | A validation study of manual atrophy measures in patients with Multiple Sclerosis | Neuroradiology | 2020 | 10 |
28 | Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings | Multiple Sclerosis and Related Disorders | 2021 | 10 |
29 | Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI | European Radiology | 2017 | 5 |
30 | Impact of COVID-19 pandemic on frequency of clinical visits, performance of MRI studies, and therapeutic choices in a multiple sclerosis referral centre | Journal of Neurology | 2022 | 5 |
31 | Biopsychosocial Response to the COVID-19 Lockdown in People with Major Depressive Disorder and Multiple Sclerosis | Journal of Clinical Medicine | 2022 | 5 |
32 | The ACROSS study: Long-term efficacy of fingolimod in patients with relapsing–remitting multiple sclerosis | Multiple Sclerosis Journal - Experimental, Translational and Clinical | 2020 | 4 |
33 | Editorial | Multiple Sclerosis Journal | 2019 | 3 |
34 | Secondary progressive NMO, or concomitant NMO and a primary neurodegenerative disorder? | Multiple Sclerosis Journal | 2015 | 2 |
35 | Prognosis of a second clinical event from baseline MRI in patients with a CIS: a multicenter study using a machine learning approach | Neuroradiology | 2022 | 2 |
36 | Commentary on Pique et al.’s paper entitled: Peripheral late reactivation of a previously typical monofocal Balo’s concentric sclerosis lesion | Multiple Sclerosis Journal | 2015 | 1 |
37 | Can Cognitive training Reignite Compensatory Mechanisms in Advanced Multiple Sclerosis Patients? An Explorative Morphological Network Approach | Neuroscience | 2022 | 0 |